

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047331 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 16/28**,  
C12N 15/13, 15/63, 5/10, A61K 39/395, A61P 35/00,  
37/00

98040 (US). ZHOU, Hongxing [CN/US]; 6324 - 151st Avenue S.E., Bellevue, WA 98006 (US).

(21) International Application Number:  
PCT/US2004/037242

(74) Agent: MACHIN, Nathan A.; 1201 Amgen Court West, Seattle, WA 98119-3105 (US).

(22) International Filing Date:  
4 November 2004 (04.11.2004)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/518,166 7 November 2003 (07.11.2003) US

(71) Applicant (for all designated States except US): **IMMUNEX CORPORATION** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARTER, Paul J.** [US/US]; 4312 - 86th Avenue S.E., Mercer Island, WA

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR

	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
L1	EVLTQSPGTLSPQERATLS	CRASQFVSSSTLAWYQK	PCQAPRLITFQA	SRRAITFDRFSGSGSGTDF	TLTISRLEPEDFAV	YTCQYUSEPPTFG	GGTKVEIK
L2	-----S-----	-----Y-----	-----P-----	-----D-----	-----M-----	-----R-----	-----D-----
L3	-----T-H-D-----	-----Y-----	-----S-----	-----P-----	-----I-----	-----R-----	-----D-----
L4	-----N-----	-----D-----	-----Y-----	-----S-----	-----P-----	-----I-----	-----D-----
L5	D-----A-----	N-----H-----	Y-----T-----	Y-----T-----	T-----	-----	RL-----
L6	D-----T-A-----	G-----	R-----	Y-----	-----	-----	N-----

  

	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
H1	EVQLVQSGGGLVHGGSLRLSCAGSGPTFS	RDAWVWQA	PGGLEWVSGITGCA	ITVADSVKRF	TSRDNAKNSLYLQ	MNSLRADENAV	TYCARGITFYD
H2	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H3	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H4	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H5	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H6	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H7	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H8	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H9	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H10	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H11	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H12	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H13	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H14	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H15	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H16	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H17	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H18	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H19	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H20	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H21	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H22	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H23	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----
H24	-----Q-----	-----A-----	-----S-----	-----S-----	-----S-----	-----S-----	-----S-----

(57) Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.



**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*